2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 133

GBR830, a True OX40 Antagonist Antibody with Potent Suppressive Effects on T Cell-Mediated Pathological Responses
Abstract Number: 134

Exploration of T-Cell Signatures Following TCR Stimulation Using Single Cell RNA-Seq to Inform Treatment Response Studies in Rheumatoid Arthritis
Abstract Number: 135

High Dimensional Analysis By Mass Cytometry and RNA-Sequencing Reveals Altered Frequency and Exhausted Features of CD4 T and MAIT Cells in Systemic Sclerosis
Abstract Number: 136

Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in Multiple Mouse Models of Autoimmunity
Abstract Number: 137

Autoantibody-Inducing CD4 T (aiCD4 T) Cells Which Induce Systemic Lupus Erythematosus (SLE) Contain Follicular Helper T Cell in Addition to the Major IL-21-Producing CXCR5-ICOShiPD1hi Population: Self-Organized Criticality Theory As the Cause of SLE
Abstract Number: 138

Distinct Roles of Tfh2, SLAMF7+ Tfh1 Cells and Th1 Cells in the Pathogenesis of IgG4-RD
Abstract Number: 139

Calcium/Calmodulin-Dependent Protein Kinase 4 Promotes GLUT1-Dependent Glycolysis in Systemic Lupus Erythematosus
Abstract Number: 140

Inhibition of Cathepsin S Leads to Suppression of SS-a/SS-B Specific T Cells from Patients with Primary Sjøgren Syndrome
Abstract Number: 141

Lymphocyte Activation Gene 3 Plasma Level Is Increased and Associated with Progression in Early Rheumatoid Arthritis
Abstract Number: 142

Peripheral CD4+CD25+Foxp3+T Regulatory Cells Absolutely Reduce in Patients with Systemic Lupus Erythematosus
Abstract Number: 143

Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells
Abstract Number: 144

Small Molecule Inhibitor of Bcl-6 Reduces the Tfh Population in Peripheral Blood, Splenic Germinal Center and Ankle Joints in a Collagen-Induced Arthritis Mouse Model of RA
Abstract Number: 145

1,25(OH)2D3 and Dexamethasone Additively Suppress Synovial Fibroblast Activation By CCR6+ T-Helper Memory Cells and Enhance the Effect of Tnfα Blockade
Abstract Number: 146

Mesenchymal Stromal Cell Transferred Mitochondria Elicit an Immune Function Reprogramming That Entails T Regulatory Cell Commitment and Clinical Improvement of Graft Vs Host Disease
Abstract Number: 147

T Follicular Helper Cell Phenotype in RA Patients Receiving Rituximab

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].